The effects of obesity on drug pharmacokinetics in humans

Bibliography

• World Health Organization. Obesity and overweight. Fact Sheet 311 2006
   Google Scholar
• Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9:(Suppl 4):326S-334S
   Google Scholar
• National Institute of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. US Department of Health and Human Services, Bethesda, MD; 1998
   Google Scholar
• Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007;121(7):492-6
   PubMed Web of Science ®Google Scholar
• Martinez M, Mahmood I, Hunter RP. Allometric scaling of clearance in dogs. J Vet Pharmacol Ther 2009;32(5):411-16
   PubMed Web of Science ®Google Scholar
• Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157(6):907-21
   PubMed Web of Science ®Google Scholar
• Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58(2):119-33
   PubMed Web of Science ®Google Scholar
• Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 2009;11(2):262-76
   PubMed Web of Science ®Google Scholar
• Feng B, LaPerle JL, Chang G, Varma MV. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. Expert Opin Drug Metab Toxicol 2010;6(8):939-52
   PubMed Web of Science ®Google Scholar
• Forbes GB, Welle SL. Lean body mass in obesity. Int J Obes 1983;7(2):99-107
   PubMed Web of Science ®Google Scholar
• Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88(1):1-7
   PubMed Web of Science ®Google Scholar
• Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39(3):215-31
   PubMed Web of Science ®Google Scholar
• Lemmens HJ. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol 2010;23(4):485-91
   PubMed Web of Science ®Google Scholar
• Han PY, Kirkpatrick CM, Green B. Informative study designs to identify true parameter-covariate relationships. J Pharmacokinet Pharmacodyn 2009;36(2):147-63
   PubMed Web of Science ®Google Scholar
• Young JF, Luecke RH, Pearce BA, Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J Toxicol Environ Health A 2009;72(8):527-40
   PubMed Web of Science ®Google Scholar
• de la Grandmaison GL, Clairand I, Durigon M. Organ weight in 684 adult autopsies: new tables for a Caucasoid population. Forensic Sci Int 2001;119(2):149-54
   PubMed Web of Science ®Google Scholar
• Ogiu N, Nakamura Y, Ijiri I, A statistical analysis of the internal organ weights of normal Japanese people. Health Phys 1997;72(3):368-83
   PubMed Web of Science ®Google Scholar
• Singh D, Bansal YS, Sreenivas M, Weights of human organs at autopsy in Chandigarh zone of North-west India. J Indian Assoc Forens Med 2004;26:97-9
   Google Scholar
• Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991;49(6):163-75
   PubMed Web of Science ®Google Scholar
• Janmahasatian S, Duffull SB, Ash S, Quantification of lean bodyweight. Clin Pharmacokinet 2005;44(10):1051-65
   PubMed Web of Science ®Google Scholar
• Nawaratne S, Brien JE, Seeman E, Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 1998;46(5):447-52
   PubMed Web of Science ®Google Scholar
• Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007;82(5):505-8
   PubMed Web of Science ®Google Scholar
• McLeay SC, Morrish GA, Kirkpatrick CM, Green B. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 2009;26(7):1626-34
   PubMed Web of Science ®Google Scholar
• Pietilainen KH, Rissanen A, Kaprio J, Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol Endocrinol Metab 2005;288(4):E768-74
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1):91-100
   PubMed Web of Science ®Google Scholar
• Rinella ME, Alonso E, Rao S, Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001;7(5):409-14
   PubMed Web of Science ®Google Scholar
• Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977;56(4 Pt 1):605-12
   PubMed Web of Science ®Google Scholar
• Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg 2006;16(6):773-6
   PubMed Web of Science ®Google Scholar
• Jansson PA, Larsson A, Lonnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998;28(10):813-18
   PubMed Web of Science ®Google Scholar
• Summers LK, Samra JS, Humphreys SM, Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996;91(6):679-83
   PubMed Web of Science ®Google Scholar
• Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993;306(2):117-23
   PubMed Web of Science ®Google Scholar
• Chinali M, Devereux RB, Howard BV, Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004;93(1):40-4
   PubMed Web of Science ®Google Scholar
• Collis T, Devereux RB, Roman MJ, Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001;103(6):820-5
   PubMed Web of Science ®Google Scholar
• Luecke RH, Pearce BA, Wosilait WD, Postnatal growth considerations for PBPK modeling. J Toxicol Environ Health A 2007;70(12):1027-37
   PubMed Web of Science ®Google Scholar
• Alexander JK, Dennis EW, Smith WG, Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962;1:39-44
   PubMedGoogle Scholar
• Danias PG, Tritos NA, Stuber M, Cardiac structure and function in the obese: a cardiovascular magnetic resonance imaging study. J Cardiovasc Magn Reson 2003;5(3):431-8
   PubMed Web of Science ®Google Scholar
• de Simone G, Devereux RB, Daniels SR, Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 1997;95(7):1837-43
   PubMed Web of Science ®Google Scholar
• Messerli FH, Ventura HO, Reisin E, Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982;66(1):55-60
   PubMed Web of Science ®Google Scholar
• Palmieri V, de Simone G, Arnett DK, Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol 2001;88(10):1163-8
   PubMed Web of Science ®Google Scholar
• Stelfox HT, Ahmed SB, Ribeiro RA, Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med 2006;34(4):1243-6
   PubMed Web of Science ®Google Scholar
• Albertin A, Poli D, La Colla L, Predictive performance of 'Servin's formula' during BIS-guided propofol-remifentanil target-controlled infusion in morbidly obese patients. Br J Anaesth 2007;98(1):66-75
   PubMed Web of Science ®Google Scholar
• La Colla L, La Colla G, Albertin A, The use of propofol and remifentanil for the anaesthetic management of a super-obese patient. Anaesthesia 2007;62(8):842-5
   PubMed Web of Science ®Google Scholar
• Barras MA, Duffull SB, Atherton JJ, Green B. Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther 2008;83(6):882-8
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49(2):71-87
   PubMed Web of Science ®Google Scholar
• Keys A, Fidanza F, Karvonen MJ, Indices of relative weight and obesity. J Chronic Dis 1972;25(6):329-43
   PubMedGoogle Scholar
• Du Bois D, Du Bois EF. Clinical calorimetry. Tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863
   Google Scholar
• Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317(17):1098
   PubMed Web of Science ®Google Scholar
• Devine D. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-5
   Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988;6(8):1321-7
   PubMed Web of Science ®Google Scholar
• Duffull SB, Dooley MJ, Green B, A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004;43(15):1167-78
   PubMed Web of Science ®Google Scholar
• James W. Research on Obesity. London: Her Majesty's Stationery Office 1976
   Google Scholar
• Green B, Duffull S. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002;72(6):743-4
   PubMed Web of Science ®Google Scholar
• Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002;42(6):620-43
   PubMed Web of Science ®Google Scholar
• Jung D, Mayersohn M, Perrier D, Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 1982;56(4):269-74
   PubMed Web of Science ®Google Scholar
• Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45(1):48-56
   PubMed Web of Science ®Google Scholar
• Pai MP, Norenberg JP, Anderson T, Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007;51(8):2741-7
   PubMed Web of Science ®Google Scholar
• Sanderink GJ, Le Liboux A, Jariwala N, The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72(3):308-18
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007;25(30):4707-13
   PubMed Web of Science ®Google Scholar
• Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994;26(4):292-307
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. Arch Neurol 1985;42(5):468-71
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 1984;9(2):177-83
   PubMed Web of Science ®Google Scholar
• Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 1984;18(6):941-6
   PubMed Web of Science ®Google Scholar
• Derry CL, Kroboth PD, Pittenger AL, Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J Clin Psychopharmacol 1995;15(3):197-205
   PubMed Web of Science ®Google Scholar
• Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20(11):2305-13
   PubMed Web of Science ®Google Scholar
• Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983;24(5):643-7
   PubMed Web of Science ®Google Scholar
• Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008;294(4):F685-96
   PubMedGoogle Scholar
• Chagnac A, Herman M, Zingerman B, Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008;23(12):3946-52
   PubMed Web of Science ®Google Scholar
• Blackburn GL, Hutter MM, Harvey AM, Expert panel on weight loss surgery: executive report update. Obesity (Silver Spring) 2009;17(5):842-62
   PubMed Web of Science ®Google Scholar
• Navarro-Diaz M, Serra A, Romero R, Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006;17(12 Suppl 3):S213-7
   PubMedGoogle Scholar
• Saliba J, Kasim NR, Tamboli RA, Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery;147(2):282-7
   PubMed Web of Science ®Google Scholar
• Serpa Neto A, Bianco Rossi FM, Dal Moro Amarante R, Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J Nephrol 2009;22(5):637-46
   PubMed Web of Science ®Google Scholar
• Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66(7):642-8
   PubMed Web of Science ®Google Scholar
• Ozmen S, Kaplan MA, Kaya H, Role of lean body mass for estimation of glomerular filtration rate in patients with chronic kidney disease with various body mass indices. Scand J Urol Nephrol 2009;43(2):171-6
   PubMed Web of Science ®Google Scholar
• Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010;17(5):e53-62
   PubMedGoogle Scholar
• Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003;56(1):96-103
   PubMed Web of Science ®Google Scholar
• Ekhart C, Rodenhuis S, Schellens JH, Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 2009;64(1):115-22
   PubMed Web of Science ®Google Scholar
• Schmitt A, Gladieff L, Lansiaux A, A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 2009;15(10):3633-9
   PubMed Web of Science ®Google Scholar
• Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010;429(3):435-49
   PubMedGoogle Scholar
• Sissung TM, Baum CE, Kirkland CT, Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 2010;44(2):152-67
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet 1986;11(3):199-213
   PubMed Web of Science ®Google Scholar
• Videau O, Delaforge M, Levi M, Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun Mass Spectrom 2010;24(16):2407-19
   PubMed Web of Science ®Google Scholar
• La Colla L, Albertin A, La Colla G, Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet 2010;49(2):131-9
   PubMed Web of Science ®Google Scholar
• Emery MG, Fisher JM, Chien JY, CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38(2):428-35
   PubMed Web of Science ®Google Scholar
• Leclercq I, Horsmans Y, Desager JP, Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998;28(3):410-16
   PubMed Web of Science ®Google Scholar
• Su GM, Sefton RM, Murray M. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid. J Pharmacol Exp Ther 1999;291(3):953-9
   PubMed Web of Science ®Google Scholar
• Donato MT, Jimenez N, Serralta A, Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 2007;21(2):271-6
   PubMed Web of Science ®Google Scholar
• Donato MT, Lahoz A, Jimenez N, Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 2006;34(9):1556-62
   PubMed Web of Science ®Google Scholar
• Greenman CG, Jagielski CH, Griggs JJ. Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer 2008;112(10):2159-65
   PubMed Web of Science ®Google Scholar